Data published -European Journal of Heart Failure

AI SummaryClose X

Shield Therapeutics plc announced positive results from the ORION-HF study, published in the European Journal of Heart Failure, demonstrating the efficacy and safety of FeRACCRU® (ferric maltol) in patients with heart failure and iron deficiency anemia. The study showed a significant increase in haemoglobin concentration from 11.4 to 12.8 g/dl after 16 weeks (p<0.001). There was also a statistically significant increase in the 6-minute walk test distance from 298 to 335 meters (p<0.001) and an increase in the Kansas City Cardiomyopathy Questionnaire overall summary score from 65 to 76 points (p=0.004). Furthermore, statistically significant improvements were observed in other iron markers (p<0.001). The treatment was well-tolerated, with adverse events mainly GI related and consistent with previous studies.

Disclaimer*

UK 100

Latest directors dealings